- citations in SCIndeks: 0
- citations in CrossRef:0
- citations in Google Scholar:[
 ]
- visits in previous 30 days:8
- full-text downloads in 30 days:4
|
|
|
2021, vol. 37, iss. 84, pp. 2225-2225
|
|
Smoking and alcohol consumption as risk factors in 112 oncology patients diagnosed with bisphosphonate-associated osteonecrosis of the jaw
Pušenje i konzumiranje alkohola kao faktori rizika kod 112 onkoloških bolesnika sa dijagnozom bisfosfonatne osteonekroze vilica
aMedicinski univerzitet Plovdiv, Fakultet za javno zdravlje, Departman za epidemiologiju i vanredne situacije u medicini, Plovdiv, Bugarska
bMedicinski univerzitet Plovdiv, Fakultet za javno zdravlje, Departman za socijalnu medicinu i javno zdravlje, Plovdiv, Bugarska
cUniverzitet u Plovdivu, Klinika za maksilofacijalnu hirurgiju, Univerzitetska bolnica "Sveti Georgije", Plovdiv, Bugarska
Project: The paper was supported by the Ministry of Education and Science, Republic of Bulgaria (National program "Young scientists and postdoctoral students").
Abstract
Background: Bisphosphonate-associated osteonecrosis of the jaws (BAONJ) is a complication of great medical importance. Some of the most discussed and controversial aspects are the risk factors, some of which are related to patients' smoking and alcohol consumption. The Aim: To study cancer patients with BAONJ and determine their participation in the mentioned above risky health-related habits. Material and methods: A prospective epidemiological study of 112 patients diagnosed with bisphosphonate-associated osteonecrosis of the jaw in 2016 and 2017 was conducted at the Clinic of Maxillofacial surgery of University hospital "St. George", Plovdiv, Bulgaria, based on anamnesis, clinical examination, and hospital documentation. SPSS Statistics v.24 was used for statistical analysis, at a significance level p<0.05. Results: Over 2/3 of the patients were smokers (40.18%) or ex-smokers (25.00%), which linked them with the risk factor of smoking. At the time of the study, patients smoking between 1 and 9 and between 10 and 19 cigarettes a day had equal relative shares of 44.22%. More than half of the patients smoked from the age of 20-39, which we explain by the high average age. The majority of patients studied consumed alcohol, most often once a week or on weekends (28.57%) or only on occasions (26.79%), followed by 24.11% who used alcohol several times per week. Nearly 2/3 drink drinks with both low and high alcohol content. Conclusion: The highest proportion of patients are smokers / ex-smokers and consume alcoholic beverages occasionally, which links them to these risk potential factors.
Sažetak
Uvod: Osteonekroza vilica udružena sa bisfosfonatima (OVUB) je komplikacija od velikog medicinskog značaja. Neki od najkontroverznijih apsekata o kojima se najviše diskutovalo jesu faktori rizika, od kojih su neki povezani sa pušenjem i konzumacijom alkohola kod pacijenata kod kojih se osteonekroza pojavila.. Cilj: Proceniti koliki je rizik od nastajanja OVUB oboljenja kod onkoloških pacijenata sa rizičnim zdravstvenim navikama. Materijal i metode: Sprovedena je Prospektivna epidemiološka studija, je obuhvatila 112 pacijenata sa dijagnostifikovanom osteonekrozom vilice udružene sa bisfosfonatima, sprovedena je na Klinici za maksilofacijalnu hirurgiju Univerzitetske bolnice "Sveti Georgije" u Plovdivu, u Bugarskoj, u periodu od 2016. i 2017. godinu, na osnovu anamneze, kliničkog pregleda i pregleda bolničke dokumentacije. Za statističku analizu korišćen je SPSS program v.24, sa nivoom značajnosti postavljenim na p < 0,05. Rezultati: Preko 2/3 pacijenata bili su pušači (40,18%) ili bivši pušači (25,00%), što ih povezuje sa faktorom rizika-pušenjem. U vreme studije, pušači koji su pušili između 1 cigarete i 9 cigareta i između 10 i 19 cigareta dnevno imali su jednak relativni udeo od 44,22%. Više od polovine pacijenata koji su pušili starosti su između 20 i 39 godina, odosno bili su sa visokom prosečnom starošću. Većina ispitivanih pacijenata konzumirala je alkohol, najčešće jednom nedeljno ili vikendom (28,57%) ili samo povremeno (26,79%), a 24,11% unosilo je alkohol nekoliko puta nedeljno. Skoro 2/3 ispitanika konzumiralo je piće i sa niskim i sa visokim sadržajem alkohola. Zaključak: Najveći broj pacijenata bili su pušači/bivši pušači i povremeni konzumenti alkohola, što ih ukazuje da su pušenje i alkohol potencijalni faktori rizika za razvoj bisfosfonatne osteonekroze vilica.
|
|
|
|
References
|
|
|
*** (2010) Guideline: Prevention of osteonecrosis of the jaw (ONJ) in patients on bisphosphonate therapies. NWS health, https://www.aub.edu.lb/fm/CaMOP/Documents/G L2010_010.pdf (Accessed on September 28, 2020)
|
|
  
|
Almazrooa, S.A., Woo, S.B. (2009) Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: A review. Journal of the American Dental Association, 140(7): 864-875
|
|
|
Campisi, G., Fedele, S., Fusco, V., Pizzo, G., di Fede, O., Bedogni, A. (2014) Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncology, 10(2): 257-275
|
|
|
Ficarra, G., Beninati, F. (2007) Bisphosphonte-related osteonecrosis of the jaws: The point of view of the oral pathologist. Clin Cases Miner Bone Metab, 4: 53-7
|
|
|
Frazer-Cox, C. (2020) New MRONJ guidance. British Dental Journal, 229(3): 151-151
|
|
|
Izzotti, A., Menini, M., Pulliero, A., Dini, G., Cartiglia, C., Pera, P., Baldi, D. (2013) Biphosphonates-associated osteonecrosis of the jaw: The role of geneenvironment interaction. J Prev Med Hyg, 54(3): 138-183
|
|
|
Lee, L.W., Hsiao, S.H., Chen, L.K. (2014) Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. Journal of the Formosan Medical Association, 113(3): 166-172
|
|
|
Lu, S.Y., Liang, C.C., Lin, L.H. (2014) Retrospective analysis of 27 cases of bisphosphonate-related osteonecrosis of the jaw treated surgically or nonsurgically. Journal of Dental Sciences, 9(2): 185-194
|
|
|
Marx, R.E. (2016) Risk factors for antiresorptive drugrelated osteonecrosis of the jaw. in: Fleisher Kenneth E.; Kontio Risto; Otto Sven [ed.] Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)-a Guide to Research, 39-44
|
|
|
Payne, K.F., Goodson, A.M., Tahim, A.S., Rafi, I., Brennan, P.A. (2017) Why worry about bisphosphonate-related osteonecrosis of the jaw?: A guide to diagnosis, initial management, and referral of patients. British Journal of General Practice, 67(660): 330-331
|
|
|
Pešić, Z., Zarev, M., Ranđelović, J. (2016) How much we know about bisphosphonate lesions. Acta stomatologica Naissi, vol. 32, br. 73, str. 1546-1554
|
|
|
Quispe, D., Shi, R., Burton, G. (2011) Osteonecrosis of the jaw in patients with metastatic breast cancer: Ethnic and socio-economic aspects. Breast Journal, 17(5): 510-513
|
|
1
|
Ruggiero, S.L., Dodson, T.B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., O'Ryan, F. (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. Journal of Oral and Maxillofacial Surgery, 72(10): 1938-1956
|
|
|
Tenore, G., Palaia, G., Gaimari, G. (2014) Medication-related osteonecrosis of the jaws (MRONJ): Etiological update. Senses Sci, 1(4): 147-152
|
|
|
Thumbigere-Math, V., Tu, L., Huckabay, S., Dudek, A.Z., Lunos, S., Basi, D.L., Hughes, P.J., Leach, J.W., Swenson, K.K., Gopalakrishnan, R. (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American Journal of Clinical Oncology, 35(4): 386-392
|
|
|
Wang, Q., Liu, J., Qi, S., Liao, X., Liu, D., Pan, J. (2018) Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China. Journal of Dental Sciences, 13(3): 190-197
|
|
|
Watters, A.L., Hansen, H.J., Williams, T., Chou, J.F., Riedel, E., Halpern, J., Tunick, S., Bohle, G., Huryn, J.M., Estilo, C.L. (2013) Intravenous bisphosphonate-related osteonecrosis of the jaw: Long-term follow-up of 109 patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 115(2): 192-200
|
|
|
Wei, L.Y., Kok, S.H., Lee, Y.C., Chiu, W., Wang, J., Cheng, S., Chang, H., Lee, J.C. (2021) Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid. Journal of the Formosan Medical Association, 120(8): 1572-1580
|
|
|
Wessel, J.H., Dodson, T.B., Zavras, A.I. (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. Journal of Oral and Maxillofacial Surgery, 66(4): 625-631
|
|
|
Woo, S.B., Hellstein, J.W., Kalmar, J.R. (2006) Systematic review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144(10): 753-753
|
|
|
|
|